Clavister: Solid Q3, on track for positive EBIT 2025e - ABG

EBITDA +6% vs ABGSC and EBIT turned positive in Q3
We expect consensus to lift 2024 EBITDA by 10-15% and '25e-'26e by ~5%
Increased conviction in positive EBIT 2025e


Q3 details

Continued solid growth and better margins in Q3. Sales SEK 44m (-1% vs ABGSC 44m). FX adjusted growth 21% (vs ABGSC 21%). Order intake SEK 37m (+31% y-o-y), ARR SEK 127m (+10% y-o-y). EBITDA SEK 11m (+6% vs ABGSC 10m). EBIT SEK 1m (vs ABGSC -1m). Non-recurring items of SEK 1m also impacted reported EBIT and EBITDA negatively. Adjusted EBITDA was SEK 12m (25% margin). Operating cash flow SEK 2m (SEK -4m working capital) and free cash flow SEK -7m. YTD operating cash flow was SEK -1m and management guides for it to turn positive on full-year 2024. After Q3 ended, Clavister received SEK 50m before transaction fees from the warrant series TO8 (98% subscription rate), which should lead to a significant reduction of the net debt (SEK 203m in Q3).

Länk till analysen i sin helhet: https://cr.abgsc.com/foretag/clavister/Equity-research/2024/11/clavister---solid-q3-on-track-for-positive-ebit-2025e/